echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > HepTcel, a new immunotherapy to treat chronic hepatitis B, is about to launch an international multi-center study

    HepTcel, a new immunotherapy to treat chronic hepatitis B, is about to launch an international multi-center study

    • Last Update: 2021-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The World Health Organization estimates that chronic hepatitis B (CHB) affects 292 million people worldwide and kills nearly 900,000 people each year from complications of the disease.
    chB is incurable and the antiviral drugs currently available can only control the disease and require lifelong treatment.
    these treatments have a huge financial burden on CHB patients.
    treatment, CHB can lead to serious health problems, including cirrhosis, liver failure and liver cancer.
    in patients with chronic infections, high viral loads can induce immune tolerance, preventing T cells from removing the source of infection.
    restoring T-cell function is thought to be critical to achieving a functional cure defined as the disappearance of surface antigens (HBsAg) of hepatitis B in the blood.
    , the goal of the drug therapy is to reactivate the T-cell immune response.
    biopharmaceutical company Altimmune announced today that it has included its first patient in HepTcell's Multi-Country Phase II clinical trial, a new peptide-based immunotherapy being developed to treat chronic hepatitis B (CHB).
    the study, which is being conducted in the United States, Canada and Europe, was a double-blind, randomized, placebo-controlled study of 80 CHB patients.
    end point is the virological response, defined as a decrease in HBsAg levels from the baseline at 24 weeks.
    end points include reactivation of anti-HBV T cell responses, HBsAg removal rates, and other virological responses.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.